Aim To investigate the effect of umbilical cord-derived mesenchymal stem cells (UC-MSCs) administration among liver fibrosis experimental rat model via the regulation of angiotensin II type 1 receptor (AT1R) and platelet-derived growth factor-β (PDGF-β) due to their therapeutic potential to replace liver transplantation for advanced liver fibrosis. Yet the mechanism of action has been questionably associated with UC-MSCs fibrosis regression properties. Methods Sprague-Dawley (SD) rats (n=18) were separated into three groups (control, untreated liver fibrosis, and UC-MSCs treated group). Serum PDGF-β level was determined by enzymelinked immunosorbent assay (ELISA) following 14 days of UCMSCs injection. Meanwhile, AT1R expression was interpreted based on immunoreactive score (IRS) stained using polyclonal antibody and liver fibrosis stained with hematoxylin & eosin was graded using the METAVIR score. Results UC-MSCs were isolated successfully from rat umbilical cord. Liver fibrosis was observed following 14 weeks of CCl4 injection concurrent with higher serum level of PDGF-β, but the UC-MSCs-treated group had lower level (980.08 ±289.41 and 606.42±109.85 for untreated liver fibrosis and UC-MSCs treated group, respectively; p=0.004). There was also a high expression of AT1R among untreated liver fibrosis group, as well as highgrade liver fibrosis versus localized fibrosis and low level of AT1R expression among UC-MSCs treated-group (p=0.001). Conclusion UC-MSCs administration could ameliorate liver fibrosis by reducing the AT1R expression and PDGF-β serum levels, and intervention through this signaling pathway could be alternative evidence for the causative of positive outcome.
Ezhilarasan D, Sokal E, Najimi M. Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets. Hepatobiliary Pancreat Dis Int 2018:192–7.
2
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatol 1996:289–93.
3
Remmele W, Stegner H. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987:138–40.
4
Fortea J, Fernandez-Mena C, Puerto M, Ripoll C, Almagro J, Banares J, et al. Comparison of two protocols of carbon tetrachloride-induced cirrhosis in rats -improving yield and reproducibility. Sci Rep 2018:9163.
5
Chen C, Li X, Wang L. Thymosin β4 alleviates cholestatic liver fibrosis in mice through downregulating PDGF/PDGFR and TGFβ/Smad pathways. Digest Liver Dis 2020:324–30.
6
Lu B, Xu Y, Xu L, Cong X, Yin L, Li H, et al. Mechanism investigation of dioscin against CCl4 induced acute liver damage in mice. Environ Toxicol Phar 2012:127–35.
7
Wang R, Wang J, Song F, Li S, Yuan Y. Tanshinol ameliorates CCl 4 induced liver fibrosis in rats through the regulation of Nrf2/HO-1 and NF-κB/ IκBα signaling pathway. Drug Des Dev Ther 2018:1281–92.
8
Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 2011:225–31.
9
Perepelyuk M, Terajima M, Wang A, Georges P, Janmey P, Yamauchi M, et al. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol 2013:605–14.
10
Foo N, Lin S, Lee Y, Wu M, Wang Y. Lipoic acid inhibits liver fibrosis through the attenuation of ROS-triggered signaling in hepatic stellate cells activated by PDGF and TGF-β. Toxicology 2011:39–46.
11
Underwood W, Anthony R, Cartner S, Corey D, Grandin T, Greenacre C, et al. AVMA guidelines for the euthanasia of animals: 2013 edition 2013.
12
Berardis S, Sattwika P, Najimi M, Sokal E. Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects. World J Gastroentero 2015:742.
13
Sriramulu S, Banerjee A, Liddo D, Jothimani R, Gopinath G, Murugesan M, et al. Concise review on clinical applications of conditioned medium derived from human umbilical cordmesenchymal stem cells (UC-MSCs). Int J Hematol Oncol Stem Cell Res 2018:230.
14
Zhang L, Peng X, Fang X, Li J, Chen H, Mao X. Human umbilical cord mesenchymal stem cells inhibit proliferation of hepatic stellate cells in vitro. Int J Mol Med 2018:2545–52.
15
Putra A, Antari A, Retnokustiyah A, Sorayanurintan Y, Anna C, Sadyah N, et al. Mesenchymal stem cells accelerate liver regeneration in acute liver failure animal model. Biomed Res Ther 2018:2802–10.
16
Munshi M, Uddin M, Glaser S. The role of the renin-angiotensin system in liver fibrosis. Exp Biol Med 2011:557–66.
17
Okamoto K, Tajima H, Nakanuma S, Sakai S, Makino I, Kinoshita J, et al. Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma. Int J Oncol 2012:573–82.
18
Moreno M, Bataller R. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin Liver Dis 2008:825–52.
19
Yong K, Li Y, Liu F, Gao B, Lu T, Abas W, et al. Paracrine effects of adipose-derived stem cells on matrix stiffness-induced cardiac myofibroblast differentiation via angiotensin II type 1 receptor and Smad7. Sci Rep 2016:33067.
20
Alfaifi M, Eom Y, Newsome P, Baik S. Mesenchymal stromal cell therapy for liver diseases. J Hepatol 2018:1272–85.
21
Yoshiji H, Kuriyama S, Yoshii J. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatol 2001:745–50.
22
Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res 2018:1–17.
23
Asrani S, Devarbhavi H, Eaton J, Kamath P. Burden of liver diseases in the world. J Hepatol 2019:151–71.
24
Mokdad A, Lopez A, Shahraz S, Lozano R, Mokdad A, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014:145.
25
Liu Y, Wang Z, Kwong S, Lui E, Friedman S, Li F, et al. Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 2011:612–25.
26
Lei X, Fu W, Kaneyama J, Omoto T, Miyazaki T, Li B, et al. Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice. J Hepatol 2016:110–7.
27
Hernandez-Gea V, Friedman S. Pathogenesis of liver fibrosis. Annu Rev Pathol Mech Dis 2011:425–56.
28
Gressner A, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2006:76–99.
29
Yoshida S, Ikenaga N, Liu S, Peng Z, Chung J, Sverdlov D, et al. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterol 2014:1378–92.
30
Borkham-Kamphorst E, Weiskirchen R. The PDGF system and its antagonists in liver fibrosis. Cytokine Growth F R 2016:53–61.
31
Friedman S. Liver fibrosis-from bench to bedside. J Hepatol 2003:38–53.
32
Bataller R, Ginès P, Nicolás J, Görbig M, Garcia-Ramallo E, Gasull X, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterol 2000:1149–56.
33
Bataller R, Ginès S-BP, Lora P, J, Solé A-GA, Colmenero M, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterol 2003:117–25.
34
Shim K, Eom Y, Kim M, Kang S, Baik S. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. Korean J Intern Med 2018:453–61.
35
Zhang Y, Yang X, Wu P, Xu L, Liao G, Yang G. Expression of angiotensin II type 1 receptor in rat hepatic stellate cells and its effects on cell growth and collagen production. Horm Res 2003:105–10.
36
Kanno K, Tazuma S, Chayama K. AT1R-deficient mice show less severe progression of liver fibrosis induced by CCl 4. Biochem Biophys Res Commun 2003:177–83.
37
Forbes S, Gupta S, Dhawan A. Cell therapy for liver disease: from liver transplantation to cell factory. J Hepatol 2015:157–69.
38
Raphael P, Mahou R, Morel P. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice. J Hepatol 2015:634–41.
39
Yin F, Wang W, Jiang W. Human umbilical cord mesenchymal stem cells ameliorate liver fibrosis in vitro and in vivo: from biological characteristics to therapeutic mechanisms. World J Stem Cells 2019:548–64.
40
Tsuchiya A, Takeuchi S, Watanabe T, Yoshida T, Nojiri S, Ogawa M, et al. Mesenchymal stem cell therapies for liver cirrhosis: MSCs as “conducting cells” for improvement of liver fibrosis and regeneration. Inflamm Regen 2019:1–6.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
